PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34251183-4 2021 Two approaches were established based on an orthogonal fluorenylmethyloxycarbonyl (Fmoc)-protection strategy to enable a modular buildup of an albumin-binding DOTA conjugate (known as OxFol-1) using folic acid (oxidized folate version) as a targeting agent. Folic Acid 199-209 albumin Homo sapiens 143-150 33775768-0 2021 Mechanistic insight into glycation inhibition of human serum albumin by vitamin B9: Multispectroscopic and molecular docking approach. Folic Acid 72-82 albumin Homo sapiens 55-68 34251183-9 2021 Radiolabeling with lutetium-177 was feasible at high molar activity, and the resulting radioconjugates were stable over at least 24 h. Biodistribution and SPECT/CT imaging studies confirmed the favorable effect of an albumin-binding entity to increase the tumor uptake and reduce kidney retention of folate radioconjugates. Folic Acid 300-306 albumin Homo sapiens 217-224 34202848-0 2021 Paclitaxel-Loaded Folate-Targeted Albumin-Alginate Nanoparticles Crosslinked with Ethylenediamine. Folic Acid 18-24 albumin Homo sapiens 34-41 34319853-0 2021 Folate-methotrexate loaded bovine serum albumin nanoparticles preparation: an in vitro drug targeting cytokines overwhelming expressed immune cells from rheumatoid arthritis patients. Folic Acid 0-6 albumin Homo sapiens 34-47 34319853-1 2021 The study planned to estimate biological parameters linked to rheumatoid arthritis (RA) patients, detecting the influence of MTX and biotherapy treatments on these parameters and synthesizing methotrexate bovine serum albumin nanoparticles linked to folate (FA-MTX-BSA NPs) to reduce the overwhelming expression of inflammatory cytokines. Folic Acid 250-256 albumin Homo sapiens 212-225 31981855-0 2020 Monitoring biomolecular interaction between folic acid and bovine serum albumin. Folic Acid 44-54 albumin Homo sapiens 66-79 35533346-4 2022 folic-acid-conjugated bovine serum albumin (FA-BSA) has been used to engineer the surface of GOx@ZIF-8-l-Arg composite nanoparticles to enhance their specific recognition of tumor cells. Folic Acid 0-10 albumin Homo sapiens 29-42 35126516-0 2022 Preparation and Study of Folate Modified Albumin Targeting Microspheres. Folic Acid 25-31 albumin Homo sapiens 41-48 35126516-1 2022 In this study, folate modified bovine serum albumin was successfully synthesized, while preparation of Nintedanib albumin microspheres (ND-FSA NPs) as a carrier was carried out via electrospinning technology. Folic Acid 15-21 albumin Homo sapiens 38-51 33443337-10 2021 Males had a significantly higher odds ratio (OR) of having folate levels below 12.2 nmol/L: OR 1.84 (95% confidence interval [95%CI] 1.66-2.05) in a non-adjusted model, and OR 2.02 (95%CI 1.82-2.27) adjusted for age, smoking status, body mass index, kidney function, albumin, and triglycerides levels. Folic Acid 59-65 albumin Homo sapiens 267-274 32919690-0 2020 Folic acid-modified bovine serum albumin nanoparticles with doxorubicin and chlorin e6 for effective combinational chemo-photodynamic therapy. Folic Acid 0-10 albumin Homo sapiens 27-40 32919690-1 2020 We herein describe a facile method to synthesize stable bovine serum albumin-based nanoparticles (BNPs) loaded with two anticancer therapeutics, doxorubicin (DOX) and a photosensitizer, chlorin e6 (Ce6), in combination with folic acid (FA) as a target cancer cell receptor for the development of an effective combined chemo and photodynamic (FA-Ce6/DOX/BNPs) therapy against cervical cancer. Folic Acid 224-234 albumin Homo sapiens 63-76 33257796-4 2020 Despite the high binding percentage of 5-aminosalicylates for human serum albumin (> 61.44%), results have shown that folic acid binding to human serum albumin protein is far greater (69.40%) compared to alpha1-acid-glycoprotein (3.45%). Folic Acid 118-128 albumin Homo sapiens 146-159 33257796-5 2020 Frontal analysis and zonal elution studies were conducted to provide an insight into the binding of folic acid to human serum albumin and potential competition with 5-aminosalicylates. Folic Acid 100-110 albumin Homo sapiens 120-133 33146801-1 2020 A miniaturized and integrated bioassay was developed based on molybdenum disulfide (MoS2) field-effect transistor (FET) functionalized with bovine serum albumin-folic acid (BSA-FA) for monitoring FOLR1. Folic Acid 161-171 albumin Homo sapiens 147-160 32993976-3 2020 Folic acid was conjugated to bovine serum albumin by amide bond at a binding rate of 9.46 +- 0.49 folate molecules per bovine serum albumin. Folic Acid 0-10 albumin Homo sapiens 36-49 32993976-3 2020 Folic acid was conjugated to bovine serum albumin by amide bond at a binding rate of 9.46 +- 0.49 folate molecules per bovine serum albumin. Folic Acid 0-10 albumin Homo sapiens 126-139 32993976-3 2020 Folic acid was conjugated to bovine serum albumin by amide bond at a binding rate of 9.46 +- 0.49 folate molecules per bovine serum albumin. Folic Acid 98-104 albumin Homo sapiens 36-49 32993976-3 2020 Folic acid was conjugated to bovine serum albumin by amide bond at a binding rate of 9.46 +- 0.49 folate molecules per bovine serum albumin. Folic Acid 98-104 albumin Homo sapiens 126-139 32523342-3 2020 Purpose: The primary aim of this study is to develop biomimetic rLips by utilizing folic acid (FA)-modified bovine serum albumin (BSA) as a replacement for apolipoprotein and demonstrate its tumor targeting and antitumor efficacy. Folic Acid 83-93 albumin Homo sapiens 115-128 35126516-2 2022 Folate modified albumin was used to enhance the targeting potential of the prepared microspheres. Folic Acid 0-6 albumin Homo sapiens 16-23 35126516-7 2022 It is worth noting that incorporation of Nintedanib into folic acid modified albumin microspheres resulted in an enhanced uptake of the drug into MCF-7 breast cancer cells coupled with higher inhibition rate. Folic Acid 57-67 albumin Homo sapiens 77-84 35126516-8 2022 Altogether, incorporation of Nintedanib into folate modified albumin microspheres is a new approach to improve water solubility and targeting effect of the drug. Folic Acid 45-51 albumin Homo sapiens 61-68 2969513-5 1988 On admission, there was a significant correlation between folate status, severity index and serum albumin and transferrin, all variables which reflect the patient"s nutritional status. Folic Acid 58-64 albumin Homo sapiens 98-105 3405341-8 1988 In order to eliminate the possibility of influencing the cytostatic activity of the derivative with byproducts of its synthesis, human serum albumin-folic acid derivative (HSA-FA) was prepared and tested by the same method. Folic Acid 149-159 albumin Homo sapiens 135-148 32985928-0 2021 Co-administration of Paclitaxel and 2-Methoxyestradiol using folate-conjugated human serum albumin nanoparticles for improving drug resistance and antitumor efficacy. Folic Acid 61-67 albumin Homo sapiens 85-98 32985928-2 2021 This research aims to co-encapsulate Paclitaxel (PTX) and the chemosensitizer 2-Methoxyestradiol (2-ME) into folate-conjugated human serum albumin nanoparticles (FA-HSANPs) to reduce multiple drug resistance and improve anti-tumor efficiency. Folic Acid 109-115 albumin Homo sapiens 133-146 31775133-0 2020 Design, insilico modelling and functionality theory of folate receptor targeted Myricetin -loaded bovine serum albumin nanoparticle formulation for cancer treatment. Folic Acid 55-61 albumin Homo sapiens 105-118 31775133-3 2020 Here, a folic acid (FA) conjugated bovine serum albumin (BSA) nanoparticles (NPs) were used to encapsulate myricetin (Myr). Folic Acid 8-18 albumin Homo sapiens 42-55 31981855-2 2020 The binding mechanism of folic acid to free bovine serum albumin (BSA) was studied using fluorescence, while the biomolecular interaction between confined-BSA and free folic acid was assessed by electrochemical methods and surface plasmon resonance. Folic Acid 25-35 albumin Homo sapiens 51-64 31729941-0 2020 New Folate-Modified Human Serum Albumin Conjugated to Cationic Lipid Carriers for Dual Targeting of Mitoxantrone against Breast Cancer. Folic Acid 4-10 albumin Homo sapiens 32-39 31729941-1 2020 AIMS: In the present work, folic acid-modified human serum albumin conjugated to cationic solid lipid nanoparticles were synthesized as nanocarriers of mitoxantrone for the treatment of breast cancer. Folic Acid 27-37 albumin Homo sapiens 59-66 30238853-0 2019 Multispectroscopic studies of the interaction of folic acid with glycated human serum albumin. Folic Acid 49-59 albumin Homo sapiens 80-93 31500030-2 2019 Briefly, DOX was conjugated to bovine serum albumin (BSA) and the complex was treated with lactobionic acid (LA) as well as folic acid (FA) to enhance drug endocytosis and targeting selectivity. Folic Acid 124-134 albumin Homo sapiens 38-51 30238853-1 2019 The interaction between glycated human serum albumin (gHSA) and folic acid (FA) was investigated by various spectroscopic techniques, such as fluorescence, circular dichroism, UV-vis absorption spectroscopy and electrophoretic light scattering technique. Folic Acid 64-74 albumin Homo sapiens 39-52 27832722-1 2017 The loading efficacy of folic acid with serum proteins human serum albumin (HSA), bovine serum albumin (BSA), and beta-lactoglobulin (beta-LG) was analyzed and the effect of acid conjugation on protein morphology was determined. Folic Acid 24-34 albumin Homo sapiens 61-74 29885392-0 2018 Folic acid conjugated bovine serum albumin: An efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells. Folic Acid 0-10 albumin Homo sapiens 29-42 29885392-1 2018 This work described a folic acid conjugated delivery of chrysin-loaded bovine serum albumin nanoparticles, which could overcome the nonspecific targeting disadvantage. Folic Acid 22-32 albumin Homo sapiens 78-91 30565175-0 2018 Synergistic delivery of 5-fluorouracil and curcumin using human serum albumin-coated iron oxide nanoparticles by folic acid targeting. Folic Acid 113-123 albumin Homo sapiens 70-77 30565175-4 2018 Furthermore, folic acid was decorated on human serum albumin by EDC and NHS coupling to confer targetability. Folic Acid 13-23 albumin Homo sapiens 53-60 27832722-1 2017 The loading efficacy of folic acid with serum proteins human serum albumin (HSA), bovine serum albumin (BSA), and beta-lactoglobulin (beta-LG) was analyzed and the effect of acid conjugation on protein morphology was determined. Folic Acid 24-34 albumin Homo sapiens 89-102 27221219-2 2016 The authors in this highlighted issue describe the synthesis and the photobiological characterizations of two photosensitizer (PS) conjugates based on beta-carboline derivatives covalently conjugated to folic acid (FA) coupled to bovine serum albumin (BSA) as a carrier system specifically targeting cancer cells overexpressing FA receptor alpha (FRalpha). Folic Acid 203-213 albumin Homo sapiens 237-250 28432945-0 2017 Exploring isoxsuprine hydrochloride binding with human serum albumin in the presence of folic acid and ascorbic acid using multispectroscopic and molecular modeling methods. Folic Acid 88-98 albumin Homo sapiens 55-68 27129905-1 2016 The goal of this work is to develop the method of preparing folate (FA)-decorated human serum albumin (HSA) loaded with nano-hydroxycamptothecin (nHCPT) nanoparticles (NPs) (FA-HSA-nHCPT-NPs) and to explore its antitumor activity in vivo and in vitro. Folic Acid 60-66 albumin Homo sapiens 94-101 32262577-4 2015 In this study, we report the use of folic acid-bovine serum albumin conjugate (BSA-FA) stabilized AuNSs (BSA-FA-AuNSs) as agents for the targeted photothermal ablation of cervical cancer cells (HeLa). Folic Acid 36-46 albumin Homo sapiens 54-67 27129905-0 2016 Pharmacokinetics and Tissue Distribution of Folate-Decorated Human Serum Albumin Loaded With Nano-Hydroxycamptothecin for Tumor Targeting. Folic Acid 44-50 albumin Homo sapiens 73-80 32262006-0 2014 Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor-targeting delivery system. Folic Acid 0-6 albumin Homo sapiens 41-54 25840270-1 2015 Folic acid (FA) functionalized magnetic bovine serum albumin (BSA) microcapsules (FA-MBMCs) were prepared by a facile sonochemical method, in which FA molecule was immobilized onto the outer walls of microcapsules as a targeting ligand and oleic acid (OA) modifying Fe3O4 magnetic nanoparticles (OA-Fe3O4 MNPs) were wrapped into the microcapsules. Folic Acid 0-10 albumin Homo sapiens 47-60 32262006-2 2014 This study exploited a folate-decorated delivery of bexarotene-loaded bovine serum albumin nanoparticles, which could solubilize the poorly water-soluble drug and overcome the nonspecific targeting disadvantage. Folic Acid 23-29 albumin Homo sapiens 77-90 32262006-3 2014 Bexarotene-loaded bovine serum albumin nanoparticles (BEX-BSANPs) were optimized by a desolvation technique, subsequently conjugated with folate by carbodiimide reaction. Folic Acid 138-144 albumin Homo sapiens 25-38 32262006-4 2014 The resultant folate-modified bexarotene-loaded bovine serum albumin nanoparticles (FA-BEX-BSANPs) showed a spherical shape, with a diameter of 195.3 +- 5.6 nm, a zeta potential of -33.64 +- 1.97 mV, and 71.28 +- 1.93 mug folate was coupled per mg BSA. Folic Acid 14-20 albumin Homo sapiens 55-68 25358257-0 2014 Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells. Folic Acid 17-23 albumin Homo sapiens 41-54 25358257-3 2014 In order to utilize FA-FR binding specificity to achieve targeted delivery of drugs into tumor cells, we prepared Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles for enhancing drug delivery in cancer cells. Folic Acid 131-137 albumin Homo sapiens 155-168 25358257-5 2014 RESULTS: We prepared folic acid (FA)-decorated bovine serum albumin (BSA) conjugated carboxymethyl-beta-cyclodextrin (CM-beta-CD) nanoparticles (FA-BSA-CM-beta-CD NPs) capable of entrapping a hydrophobic Gefitinib. Folic Acid 21-31 albumin Homo sapiens 54-67 25188308-2 2014 For this strategy, Magnetic Albumin Nanospheres (MAN), composed of superparamagnetic iron oxide nanoparticles (SPIONs) and bovine serum albumin (BSA), were covalently conjugated with folic acid (FA) ligands to enhance the targeting capability of the particles to folate receptor (FR) over-expressing tumours. Folic Acid 183-193 albumin Homo sapiens 130-143 25228802-0 2014 Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo. Folic Acid 15-25 albumin Homo sapiens 74-87 25228802-1 2014 BACKGROUND: This study aimed to generate targeted folic acid-conjugated, doxorubicin-loaded, magnetic iron oxide bovine serum albumin nanospheres (FA-DOX-BSA MNPs) that lower the side effects and improve the therapeutic effect of antitumor drugs when combined with hyperthermia and targeting therapy. Folic Acid 50-60 albumin Homo sapiens 120-133 25228802-12 2014 CONCLUSION: Folic acid-conjugated bovine serum albumin nanospheres composed of mixed doxorubicin and magnetic iron oxide cores can enable controlled and targeted delivery of anticancer drugs and may offer a promising alternative to targeted doxorubicin therapy for nasopharyngeal carcinoma. Folic Acid 12-22 albumin Homo sapiens 41-54 21421131-0 2011 Interaction of folic acid and some matrix metalloproteinase (MMP) inhibitor folate-gamma-hydroxamate derivatives with Zn(II) and human serum albumin. Folic Acid 15-25 albumin Homo sapiens 135-148 23790844-3 2013 In this study, the response of the synthetic form of folates known as folic acid to UV irradiation in the presence of beta-lactoglobulin (beta-LG), bovine serum albumin (BSA) and alpha-lactalbumin (alpha-LA) was investigated using circular dichroism, absorbance and fluorescence spectroscopy. Folic Acid 53-60 albumin Homo sapiens 155-168 23790844-3 2013 In this study, the response of the synthetic form of folates known as folic acid to UV irradiation in the presence of beta-lactoglobulin (beta-LG), bovine serum albumin (BSA) and alpha-lactalbumin (alpha-LA) was investigated using circular dichroism, absorbance and fluorescence spectroscopy. Folic Acid 70-80 albumin Homo sapiens 155-168 21185364-0 2011 Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Folic Acid 15-21 albumin Homo sapiens 39-52 21185364-2 2011 Here, we investigated cellular uptake of folic acid-conjugated human serum albumin nanoparticles (HSA NPs). Folic Acid 41-51 albumin Homo sapiens 69-82 21421131-0 2011 Interaction of folic acid and some matrix metalloproteinase (MMP) inhibitor folate-gamma-hydroxamate derivatives with Zn(II) and human serum albumin. Folic Acid 76-82 albumin Homo sapiens 135-148 21421131-1 2011 Human serum albumin binding of folic acid and its gamma-hydroxamate/carboxylate derivatives was studied by ultrafiltration and spectrofluorimetry, and it was found that the ligands exhibit a moderate binding (K(D) ~2-50 muM), and the folate-gamma-phenylalanine represents the highest conditional binding constant towards albumin. Folic Acid 31-41 albumin Homo sapiens 6-19 21499429-0 2011 Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Folic Acid 88-94 albumin Homo sapiens 112-125 21499429-2 2011 METHODS: We first used a supercritical antisolvent process to prepare micronized HCPT (nHCPT), and then folate-conjugated human serum albumin (HSA) nHCPT-loaded NPs (FA-HSA-nHCPT-NPs) were prepared using a NP-coated method combined with a desolvation technique. Folic Acid 104-110 albumin Homo sapiens 128-141 18070950-9 2008 Higher tHcy and lower folate concentrations correlated with impaired Delta RI(ALB) and increased CIMT. Folic Acid 22-28 albumin Homo sapiens 69-82 20957218-0 2010 Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Folic Acid 65-71 albumin Homo sapiens 107-120 20957218-8 2010 The amount of folate conjugation was 9.22 mug/mg of bovine serum albumin. Folic Acid 14-20 albumin Homo sapiens 59-72 19798971-0 2009 [Spectroscopic study on binding of folic acid to human serum albumin]. Folic Acid 35-45 albumin Homo sapiens 61-68 19798971-1 2009 The interaction of human serum albumin and folic acid was studied using fluorescence spectroscopy, UV absorption and synchronous fluorescence spectroscopy in the pH 7.4 Tris-HCl buffer system at different temperatures. Folic Acid 43-53 albumin Homo sapiens 31-38 20054435-0 2009 Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Folic Acid 77-83 albumin Homo sapiens 102-115 20001219-0 2010 In vitro evaluation of a Folate-bovine serum albumin-doxorubicin conjugate. Folic Acid 25-31 albumin Homo sapiens 39-52 23554608-0 2010 The preparation and characterization of folate-conjugated human serum albumin magnetic cisplatin nanoparticles. Folic Acid 40-46 albumin Homo sapiens 64-77 23554608-2 2010 To evaluate the importance of folate-conjugated human serum albumin (HSA) magnetic nanoparticles (Folate-CDDP/HSA MNP), we prepared drug-loaded Folate-CDDP/HSA MNPs and characterized their features. Folic Acid 30-36 albumin Homo sapiens 54-67 23554608-2 2010 To evaluate the importance of folate-conjugated human serum albumin (HSA) magnetic nanoparticles (Folate-CDDP/HSA MNP), we prepared drug-loaded Folate-CDDP/HSA MNPs and characterized their features. Folic Acid 98-104 albumin Homo sapiens 54-67 18070950-10 2008 A 1 microg/l increase in folate concentration was associated with 0.3 (95% CI 0.1 to 0.5) percentage point increase in Delta RI(ALB) and 0.002 (95% CI 0.001 to 0.006) mm decrease in CIMT, independent of blood pressure, smoking and vascular risk profile. Folic Acid 25-31 albumin Homo sapiens 119-132 18463447-7 2008 The folate gradient R(CSF/S) was negatively correlated with serum folate (p < 0.001, R(2) = 0.518) and to the albumin ratio, a blood-CSF barrier biomarker (beta = -0.235). Folic Acid 4-10 albumin Homo sapiens 110-117 17605895-0 2007 Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients. Folic Acid 11-21 albumin Homo sapiens 76-83 16454580-0 2006 Influence of human serum albumin on photodegradation of folic acid in solution. Folic Acid 56-66 albumin Homo sapiens 19-32 16454580-2 2006 The photodegradation of folic acid (FA) induced by ultraviolet-A (UV-A) radiation, in solution and in the presence of human serum albumin (HSA), was studied with absorption and fluorescence spectroscopy. Folic Acid 24-34 albumin Homo sapiens 124-137 17605895-9 2007 CONCLUSIONS: Folic acid and vitamin B complex co-administration effectively lowers tHcy and hs-CRP levels and increases albumin levels in stable hemodialysis subjects, underscoring their potential benefit to attenuate the state of inflammation and possibly improve the nutritional status in patients on hemodialysis. Folic Acid 13-23 albumin Homo sapiens 120-127